Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment by Robert L Boggs et al.
Boggs et al. BMC Dermatology 2014, 14:14
http://www.biomedcentral.com/1471-5945/14/14RESEARCH ARTICLE Open AccessEmployment is maintained and sick days
decreased in psoriasis/psoriatic arthritis patients
with etanercept treatment
Robert L Boggs1*, Sarolta Kárpáti2, Wenzhi Li1, Theresa Williams3, Ronald Pedersen3, Lotus Mallbris3
and Robert Gniadecki4Abstract
Background: Psoriasis and psoriatic arthritis (PsA) impair quality of life, including reduction in employment or job
duties. The PRESTA (Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis) study, a randomized,
double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe
plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment
status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population.
Methods: Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg
once weekly (QW; n = 373) for 12 weeks by subcutaneous injection. All participants then received open-label
etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization. A pharmacoeconomic
questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included
employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical
methods included analysis of covariance, t-test, Fisher’s exact test and McNemar’s test. Last-observation-carried-forward
imputation was used for missing data.
Results: Employment was at least maintained from baseline to week 24 in both dose groups (56% [BIW/QW] and
60% [QW/QW] at baseline, 61% and 60%, respectively, at week 24). Among employed participants, the proportion of
patients whose job responsibilities changed due to PsA decreased significantly from baseline to week 24 (17–23% to
5–8%; p < 0.01). Similar results were seen with job responsibility changes due to psoriasis (11–14% to 4%; p < 0.01).
The number of monthly sick days also decreased from baseline to week 24 (2.4 days for both treatment groups to
0.7 (BIW/QW) and 1.1 (QW/QW); p ≤ 0.03 for each). No significant differences between the treatment groups were
observed for any economic endpoint at any time point.
Conclusions: For patients with moderate-to-severe plaque psoriasis and PsA, etanercept treatment resulted in reducing
job responsibility changes due to disease and in reducing sick time. Effective treatment of psoriasis and PsA may reduce
missed work days.
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The prevalence of psoriatic arthritis (PsA) in patients with
psoriasis is estimated to be as high as 30%, in contrast
with a prevalence of <1% in the general population [1-3].
Both psoriasis and PsA negatively affect quality of life.
Even patients with only mild psoriasis have reported* Correspondence: bobboggs.nc@gmail.com
1Formerly of Pfizer Inc., 3921 Glenlake Garden Drive, Raleigh, NC 27612, USA
Full list of author information is available at the end of the article
© 2014 Boggs et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.problems in everyday life [4], including an inability to
work [5,6]. PsA has been implicated in absences from work
and career activities in previous studies [7,8]. However,
more information is needed regarding employment, absen-
teeism and productivity in patients with PsA. A validated
employment and productivity questionnaire that is specific
for PsA is not currently available.
Etanercept, a fully human tumor necrosis factor-soluble
receptor, is approved for the treatment of both PsA andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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strated efficacy in treating both joint and skin symptoms.
In the PRESTA (Psoriasis Randomized Etanercept
STudy in Patients with Psoriatic Arthritis) study [9-11],
the efficacy, safety and patient-reported outcomes of
two etanercept regimens were examined in patients with
both moderate-to-severe psoriasis and PsA. Employment
status and absenteeism were pre-defined outcomes of
PRESTA and were determined via a pharmacoeconomic
questionnaire.
The objective of this analysis is to examine the data
from the pharmacoeconomic questionnaire to assess the
impact of psoriasis plus PsA on working for pay and missed
work days of patients who were treated with etanercept
during the PRESTA study.
Methods
The PRESTA study was conducted between December
2005 and March 2008, primarily in Europe and included
sites in the Middle East, Asia-Pacific, Central America
and South America [9]. Participants were enrolled from
dermatology clinics based on having moderate/severe
psoriasis and active PsA (with PsA evaluated by a rheuma-
tologist or trained arthritis evaluator). In this multicenter,
randomized study, patients received either etanercept
50 mg twice weekly (BIW) or 50 mg once weekly (QW)
during the initial 12-week, double-blind period, followed
by 50 mg QW during the subsequent 12-week, open-label
period (initial randomization remained blinded; Figure 1).
Patients in the PRESTA study were aged at least 18 years,
had clinically stable, moderate-to-severe plaque psoriasis
with a body surface area involvement of ≥10% and had a
Physician Global Assessment (PGA) of psoriasis ≥3 on a
scale of 0 to 5 (0 = clear to 5 = severe). All patients had
been diagnosed with PsA that included two or more
swollen joints and two or more painful joints at screening
and baseline, patient-reported joint pain for ≥3 months
before screening and negative serum rheumatoid factorDouble-blind Period
ETN 50 mg BIW ETN 50 mg QW
Week 0 2412†
ETN 50 mg QWETN 50 mg QW
Randomization
Open-label Period*
Figure 1 Study design. *Patients/physicians remained blinded to
initial randomized treatment groups until end of open-label period.
†Primary endpoint was percent of patients achieving clear or almost
clear status on PGA of psoriasis at week 12. BIW: twice weekly; ETN:
etanercept; PGA: Physician Global Assessment; QW: once weekly.within 6 months of screening. Efficacy, safety and patient-
reported outcomes for the PRESTA study have been
published in detail [9-11].
Pharmacoeconomic outcomes
A pharmacoeconomic questionnaire was used to assess
the impact of PsA on employment, which included the
following questions:
1. Are you currently employed (working for pay)?
2. Have you changed job responsibilities in the
previous month because?i. Your arthritis prevented you from continuing
your old duties?
ii. Your psoriasis prevented you from continuing
your old duties?
3. How many hours per week were you paid to work in
the previous month?
4. How many sick days have you taken off from work
in the previous month?
Patients were asked the same questions at baseline,
week 12 and week 24. Sick leave was counted as number
of days and was not adjusted for expected/planned
number of working hours.
Statistical analysis
All patients who completed the pharmacoeconomic ques-
tionnaire were included in the employment analyses.
Only patients who were working for pay at baseline
were included in the analyses of job changes and sick
days. Statistical tests were two-tailed with an alpha of
0.05. Last-observation-carried-forward was used for
imputation of missing values. Within-group changes from
baseline in proportions were tested using McNemar’s
test; changes from baseline for continuous endpoints
were tested using t-tests. Between-group comparisons
of proportions were tested using the Cochran-Mantel-
Haenszel test; ANCOVA was used for between-group
comparisons of continuous endpoints.
Stepwise logistic regression or linear regression analyses
were conducted on predictors of employment outcomes
at weeks 12 and 24. Separate models were run for those
employed and not employed at baseline because follow-up
questions about employment characteristics were only
asked if the patient indicated that they were employed.
The following parameters were included in models used
for patients employed at baseline: age, gender, duration of
psoriasis, duration of arthritis, treatment, baseline change
of job responsibilities (yes or no) for psoriasis, baseline
change of job responsibilities (yes or no) for arthritis,
baseline sick days, baseline weekly hours worked. For
those not in employment at baseline, only age, gender,
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included as the other information was not available.
The PRESTA study was designed and performed accord-
ing to the guidelines for Good Clinical Practice and accord-
ing to the version of the Declaration of Helsinki that was
in place during the time the study was conducted.
The protocol and its amendments received independent
ethics committee or institutional review board approval
and regulatory review and approval before site initiation
and recruitment of patients (Additional file 1). All partici-
pants signed and dated an approved informed consent
form (ICF); the pharmacoeconomic questionnaire was
referenced within the ICF.
Results
A total of 752 patients were included in the modified
intent-to-treat (mITT) population (n = 379, etanercept
50 mg BIW/QW; n = 373, etanercept 50 mg QW/QW).
Baseline demographics and clinical characteristics for the
overall mITT population have been described previously;
no significant differences were observed between treat-
ment groups, with the exceptions of prior methotrexate
use and prior topical steroid use [9-11].
Most patients in this study who were of traditional
working age (<65 years old) were employed for pay
(61.0%). The proportion of male patients working for
pay (68.1%) was higher than female patients (40.3%).
Overall employment across the European, Latin American
and Asian regions were similar (57.9%, 59.4% and 54.9%,
respectively).Table 1 Baseline demographics and clinical characteristics for
subpopulation <65 years old)
Age, years
Gender, male, n (%)
Race, White, n (%)
Body mass index
Psoriasis disease duration, years
PsA disease duration, years
Physician Psoriasis Assessment (scale: 0–5; higher scores = worse psoriasis)
PASI (scale: 0–72; higher scores = worse psoriasis)
BSA affected, %
PGA of arthritis (scale: 0–100; higher scores = worse arthritis)
Swollen joints (0–68)
Tender joints (0–72)
DLQI, total (scale: 0–30; higher scores = worse dermatology-related quality of
EQ-5D Utility (scale: 0–1; higher scores = better quality of life), mean
EQ-5D VAS (scale: 1–100; higher scores = better health), mean
HAQ DI (scale: 0–3; higher scores = more disability), mean
*p < 0.01, for employed vs. not employed, one-way analysis of variance; †p < 0.01, fo
Mean (SD), unless otherwise noted.Baseline demographics and disease characteristics dif-
fered significantly between patients who were employed
and those who were not (Table 1). Those with more
severe disease and poorer quality of life were less likely
to be employed.
The proportion of patients employed increased signifi-
cantly in the 50 mg BIW/QW group from baseline (56%)
to weeks 12 (60%) and 24 (61%; p ≤ 0.003), but not in the
50 mg QW/QW group (60%, 58% and 60%, respectively;
Figure 2). However, differences between groups were not
significant at any of the three time intervals, including
baseline. The number of hours paid to work per week
was 38.3 (BIW/QW group) and 39.2 (QW/QW group) at
baseline, and remained steady at 39.5 and 41.8, respect-
ively, by week 24 (p value was not significant between
treatment groups).
Significantly higher percentages of patients reported
job changes due to arthritis (50 mg BIW/QW: 16.5%;
50 mg QW/QW: 23.0%) than due to psoriasis (10.9%
and 13.5%, respectively, p < 0.0001 for pooled treatments)
at baseline. The proportion of patients who reported
having to change job responsibilities due to arthritis or
psoriasis decreased significantly from baseline to weeks
12 and 24 in each group (p < 0.01; Figure 2). No significant
differences were observed between groups at baseline or
post-baseline in the proportion of patients who changed
job responsibilities because of arthritis or psoriasis symp-
toms (p ≥ 0.336).
At baseline, the mean number of monthly sick days
taken was 2.4 in both treatment groups; these numbersemployed vs. not employed patients (patient
Employed (n = 431) Not employed (n = 276) Total (n = 707)
43.6 (9.4)* 47.4 (10.9) 45.1 (10.2)
321 (74.5)† 133 (48.2) 454 (64.2)
386 (89.6) 238 (86.2) 624 (88.3)
27.7 (5.2) 28.3 (5.9) 28.0 (5.5)
18.0 (10.2) 19.1 (12.6) 18.4 (11.2)
6.7 (6.7) 7.5 (7.5) 7.0 (7.0)
3.6 (0.6)* 3.7 (0.7) 3.6 (0.7)
18.5 (9.5)* 21.4 (11.1) 19.6 (10.3)
28.7 (21.4)* 34.7 (23.6) 31.0 (22.5)
48.9 (20.4)* 53.2 (21.5) 50.6 (20.9)
11.4 (13.9)* 14.5 (16.8) 12.6 (15.2)
17.6 (16.8)* 22.0 (19.1) 19.4 (17.9)
life) 11.6 (7.3)* 13.8 (7.7) 12.5 (7.3)
0.55 (0.28)* 0.38 (0.35) 0.48 (0.32)
58.0 (20.7)* 51.9 (20.6) 55.6 (20.9)
0.72 (0.59)* 1.20 (0.75) 0.91 (0.69)
r employed vs. not employed, Fisher's Exact Test p-value (2-tail).
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Figure 2 Percent of patients employed and who changed job
responsibilities due to arthritis symptoms or psoriasis symptoms.
A: Percent of patients employed. *p < 0.003 for within-group comparisons
to baseline (McNemar’s test); p > 0.05 for between-group comparisons
(Cochran-Mantel-Haenszel test). B: Percent of patients employed who
changed job responsibilities in the previous month due to arthritis
symptoms. *p < 0.004 for within-group comparisons to baseline
(McNemar’s test); p > 0.05 for between-group comparisons (Cochran-
Mantel-Haenszel test). C: Percent of patients employed who changed
job responsibilities in the previous month due to psoriasis symptoms.
*p < 0.009 for within-group comparisons to baseline (McNemar’s test);
p > 0.05 for between-group comparisons (Cochran-Mantel-Haenszel
test). BIW: twice weekly; ETN: etanercept; QW: once weekly.
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groups (BIW/QW: 68.4%; QW/QW: 47.0%; p ≤ 0.031),
without significant differences between the groups
(p ≥ 0.268; Figure 3).
In those patients who were employed at baseline,
treatment with etanercept 50 mg BIW/QW remained a
significant predictor of post-baseline employment following
adjustment for predictive baseline characteristics (Table 2)
(week 12: p = 0.001; week 24: p = 0.02). Treatment group
was not a significant predictor of other post-baseline out-
comes (hours worked, sick days, or post-baseline changes
in employment due to arthritis or psoriasis), or of becom-
ing employed in those patients not employed at baseline.
In patients employed at baseline, the probability of
continued employment was also positively associated at
week 12 with the number of hours worked at baseline
(p < 0.0001) and negatively associated at week 24 with
the number of sick days at baseline (p < 0.001). Female
gender (p = 0.03) and fewer weekly hours worked (p = 0.02)
at baseline were predictors of changing job responsibilities
due to psoriasis at week 12 and week 24, respectively;
neither was predictive of changing job responsibilities
due to PsA at either post-baseline observation. The
probability of changing job responsibilities due to PsA
was negatively associated with baseline hours worked at
week 12 (p = 0.005) and week 24 (p < 0.001) and also posi-
tively associated with older age at week 24 (p < 0.001).
Baseline sick days and fewer weekly hours worked at
baseline were predictive of more sick days recorded at week
12 and week 24 (all p < 0.01). In patients not employed at
baseline, the probability of becoming employed at weeks
12 and 24 was lower for older patients and females.
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Figure 3 Mean number of sick days taken during the past month.
*p < 0.001 for within-group comparisons to baseline in BIW/QW group
(paired t-test); *p≤ 0.031 for within-group comparisons to baseline in
QW/QW group (paired t-test); p > 0.05 for between-group comparisons
(ANCOVA). ANCOVA: analysis of covariance; BIW: twice weekly; ETN:
etanercept; QW: once weekly.
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sibilities or sick days at either week 12 or 24.
Discussion
In the PRESTA trial, treatment of psoriasis and PsA
patients with etanercept over 24 weeks resulted in
maintenance of employment in both treatment groups.
Patients in the higher dose group had statistically sig-
nificant improvements in the proportions employed,
but the baseline proportions of employed patients were
lower than in the 50 mg QW/QW dose group. In addition
to the percentage of patients remaining employed, the
number of hours worked each week improved slightly
but not significantly. The majority of senior patients
(aged ≥65 years) were not employed, suggesting they
were retired and not seeking work. Among the working
age patients (aged <65 years) the group who were not
employed had more severe disease relative to the
employed group. The percentage of employed patients
from Europe who were <65 years old in this study
(61.2%, 95% CI: 57.2% – 65.1%) is slightly less than the
percentage employed in the overall population in the
European area who were aged 15 to 64 at the end of
2006 (65%) and 2007 (66%) [12].
One of the strengths of this study is that the pharmacoe-
conomic questionnaire could distinguish between employ-
ment changes due to skin disease symptoms versus arthritis
symptoms. In both treatment groups, a larger proportion
of patients reported changing job responsibilities due to
arthritis symptoms than due to psoriasis symptoms. The
proportion of patients who had to change jobs for eitherTable 2 Predictive ability of baseline characteristics on emplo
Independent variables
(X variables used
as predictors)
Dependent va
Employed Job responsibilit
change due to psor
Week 12 Week 24 Week 12 Wee
Age NS NS 1.05
(1.00, 1.11)
N
Female NS NS 3.1 (1.1, 9.0) N
Duration of psoriasis NS NS NS N
Duration of PsA NS NS NS N
ETN BIW/QW 5.2 (1.7, 15.7) 3.0 (1.1, 8.0) NS N
Baseline job change
due to psoriasis
NS NS 22.9 (7.9, 66.3) 10.9 (4.
Baseline job change
due to PsA
NS NS NS N
Baseline sick days* NS 0.94
(0.90, 0.99)
NS N
Baseline hours worked† 1.05
(1.02, 1.08)
NS NS 0.9
(0.93,
NS = Not significant.
Data for all dependent variables are odds ratio (95% confidence intervals) except Si
increase in baseline sick days. †Odds are for a one-hour increase in baseline hours wreason decreased significantly from baseline to the end of
the study.
There was a >47% reduction in sick days after 12 weeks
of treatment. These data are comparable with a previous
study that looked at treatment of active PsA with etaner-
cept over 24 months [13]. Unlike the current study,
those investigators observed a nonsignificant decline in
missed work days (absenteeism for any reason) from
0.7 days per 2 weeks at baseline to 0.3 days per month
after 2 years of treatment (p = 0.3436).
Previous studies have shown that patients with PsA
have an elevated rate of work disability relative to nor-
mal populations, consistent with our findings at baseline
[14]. In addition, etanercept treatment of PsA has been
seen to result in impediments to labor (paid or unpaid)
declining significantly over 2 years (p < 0.001) [13]. Our
study did not look specifically at impediments to work,
but the data indirectly support the previous research.
Limitations
The PRESTA study was not designed to specifically
study employment. Furthermore, the pharmacoeco-
nomic questionnaire used in the PRESTA study has not
been validated in other clinical trials. At the time this
study was conducted, work productivity questionnaires,
including the Work Productivity and Activity Index for
psoriasis [15] and for rheumatoid arthritis [16] were not
widely used. Although the pharmacoeconomic question-
naire has not undergone extensive validation, the results
are similar to other work productivity instruments [13,14].
The pharmacoeconomic questionnaire can also be viewedyment outcomes
riables (Y variable being predicted)
y
iasis
Job responsibility
change due to PsA
Sick days
k 24 Week 12 Week 24 Week 12 Week 24
S NS 1.04 (1.00, 1.09) NS NS
S NS NS NS NS
S NS NS NS NS
S NS NS NS NS
S NS NS NS NS
0, 29.9) 3.1 (1.2, 8.6) NS 2.6 (1.4, 3.8) 3.4 (1.8, 5.0)
S 4.9 (1.8, 12.9) 6.3 (2.7, 14.6) NS -1.7 (-3.0, -0.4)
S NS NS 0.17 (0.11, 0.24) 0.15 (0.08, 0.22)
6
0.99)
0.96 (0.94, 0.98) 0.95
(0.92, 0.97)
-0.04
(-0.06, -0.01)
-0.04
(-0.07, -0.01)
ck days which show slope (95% confidence intervals). *Odds are for a one-day
orked.
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to provide the appropriate information. Both arms of
PRESTA involved treatment with etanercept, thus com-
parisons with placebo were not available. However, one
might expect employment to decline slowly for patients
with PsA given the cumulative damage to joints that
can occur. The lack of a placebo arm in PRESTA raises
the possibility that some of the improvement observed
with etanercept treatment could be due to regression to
the mean although the lack of association between disease
duration and employment outcomes reduces the likeli-
hood that this problem was the primary determinant of
these results.
Conclusions
For patients with moderate to severe psoriasis and PsA,
etanercept provides economic value, in part, by reducing
changes in job responsibilities and missed work days.
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